89bio to Announce Topline Results from Phase 1b/2a Study of BIO89-100 in NASH

SAN FRANCISCO, Sept. 13, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB) today announced that the company plans to share topline safety, tolerability and efficacy data from its Phase 1b/2a study of BIO89-100 in NASH in a pre-market press release and webcast to be held on Monday, September 14, 2020. Conference Call/Webcast Details The company will host a conference call and webcast with slides at 8:30am PT (5:30am PT) tomorrow morning, September 14. Details for the live conference call are as follows: Domestic – (833) 570-1145; International – (914) 987-7092; and Passcode - 5064866. To access the live webcast and slides, please visit “Events and Presentations” under the “Investors” section of 89bio’s website at https://ir.89bio.com/events-and-presentations . Following the live audio webcast, a replay will be available on the company’s website for 90 days. About 89bio 89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of NASH and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel. For more information, visit www.89bio.com . Investor Contact: Ryan Martins Chief Financial Officer [email protected] Media Contact: Lori Rosen LDR Communications 917-553-6808 [email protected] A member of the Roche Group [email protected] 655 Montgomery Street, Suite 1500 San Francisco, CA 94111, US Home Home About About Us Our Focus Our Focus Pipeline Pipeline IR Nav Media Archive LinkedIn icon © 2026 | 89bio, Inc. All rights reserved. Trademarks are property of 89bio, Inc. | Terms of Use | Privacy Statement var s_CCSWebHostingAccount = "trcg89bio"; {"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/7021","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","themeUrl":"sites\/g\/files\/knoqqb107131\/themes\/site\/nir_pid3511"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJyNUdFuQyEI_aHmmmbZ9xBU1rqrcAN0W_9-Xl3SdtmyxQc5eORwgIsCMtarl2SB79GCWSJBxQun84H_JG4qedAiGoVa4g3sQUnC9phykRpRRzKtlIuLQkbvJ1aycAuXFxV24inQUFfywYRYJa1h9GIOil741BV6wTOq_4tuMER-4TZCBqUkrXX9_kH4vvalemm9dQyPcLxueJpO92DBV_wAzBlSRTPASur2Ay8Nqw525dStMNMc0Vby0_PxGOSNVEueDb9TtOIELH0VNDfzLbd83QfrnqmFff6fqULHDA","theme":"nir_pid3511","theme_token":null},"ajaxTrustedUrl":[],"nir_admin_use_chosen":true,"nir_admin_use_select2":false,"user":{"uid":0,"permissionsHash":"0a01461807975b1831e58f170bd7d5e5af9fce1f10b74122e7c25f8a08da69ae"}}

The release as fetched from its publisher. 89bio.com ↗